Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -113.73% is in line with its 5-year average of -110.11%, around the middle of its 5-year range (-206.50%–0.15%).
57.54% below its 12-month average of -72.19%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.15%.
OPERATING MARGIN
-113.73%
OPERATING MARGIN AVG TTM
-72.19%
OPERATING MARGIN AVG 3Y
-90.79%
OPERATING MARGIN AVG 5Y
-110.11%
OPERATING MARGIN AVG 10Y
-88.73%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-57.54%
CURRENT VS 3Y AVG
-25.26%
CURRENT VS 5Y AVG
-3.29%
CURRENT VS 10Y AVG
-28.18%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
UroGen Pharma Ltd.
Market Cap
$2.01B
Operating Margin
-113.73%
TTM Avg
-72.19%
3Y Avg
-90.79%
5Y Avg
-110.11%
Market Cap
$2.02B
Operating Margin
37.06%
TTM Avg
17.54%
3Y Avg
-25.09%
5Y Avg
-117.46%
Market Cap
$2.01B
Operating Margin
38.98%
TTM Avg
19.21%
3Y Avg
-11.92%
5Y Avg
-190.31%
Market Cap
$1.98B
Operating Margin
0.41%
TTM Avg
-3.56%
3Y Avg
0.15%
5Y Avg
-1.31%
Market Cap
$2.05B
Operating Margin
5.95%
TTM Avg
2.95%
3Y Avg
-1.94%
5Y Avg
-1.81%
Market Cap
$1.97B
Operating Margin
6.02%
TTM Avg
5.04%
3Y Avg
-2.01%
5Y Avg
-12.30%
Market Cap
$2.06B
Operating Margin
-512.91%
TTM Avg
-49765.56%
3Y Avg
-47036.35%
5Y Avg
-33558.09%
Market Cap
$2.07B
Operating Margin
-19160.00%
TTM Avg
-10969.44%
3Y Avg
-7268.29%
5Y Avg
-5243.17%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.01B | -113.73% | -72.19% | -90.79% | -110.11% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 37.06% | 17.54% | -25.09% | -117.46% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.01B | 38.98% | 19.21% | -11.92% | -190.31% |
| Progyny, Inc. (PGNY)vs › | $2.03B | 8.55% | 6.20% | 5.27% | 4.99% |
| Fortrea Holdings Inc. (FTRE)vs › | $1.98B | 0.41% | -3.56% | 0.15% | -1.31% |
| Vericel Corporation (VCEL)vs › | $2.05B | 5.95% | 2.95% | -1.94% | -1.81% |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.97B | 6.02% | 5.04% | -2.01% | -12.30% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | -512.91% | -49765.56% | -47036.35% | -33558.09% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | -19160.00% | -10969.44% | -7268.29% | -5243.17% |
| Vir Biotechnology, Inc. (VIR)vs › | $1.96B | -682.68% | -736.97% | -554.11% | -436.61% |
Gross Margin
90.8%
Operating Margin
-113.7%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | 0.15% |
| 2026-03-31 | -39.76% |
| 2025-12-31 | -50.52% |
| 2025-09-30 | -99.65% |
| 2025-06-30 | -171.17% |
| 2025-03-31 | -182.26% |
| 2024-12-31 | -112.59% |
| 2024-09-30 | -69.61% |
| 2024-06-30 | -118.27% |
| 2024-03-31 | -137.05% |
| 2023-12-31 | -62.09% |
| 2023-09-30 | -64.74% |
| 2023-06-30 | -72.77% |
| 2023-03-31 | -128.23% |
| 2022-12-31 | -112.10% |
| 2022-09-30 | -112.36% |
| 2022-06-30 | -112.71% |
| 2022-03-31 | -161.88% |
| 2021-12-31 | -123.13% |
| 2021-09-30 | -206.50% |
| 2021-06-30 | -175.13% |
| 2021-03-31 | -348.88% |
| 2020-12-31 | -342.13% |
| 2020-09-30 | -841.49% |
| 2020-06-30 | -8548.39% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | -131961.11% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | -7451.94% |
| 2018-06-30 | -5064.29% |
| 2018-03-31 | -2835.76% |
| 2017-12-31 | -3106.42% |
| 2017-09-30 | -3.88% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | -18621.05% |
| 2016-12-31 | 79.30% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
